Heterogeneity of pathogenesis in multiple sclerosis: implications for promotion of remyelination.
Enhancing myelin repair remains an important therapeutic goal in primary demyelinating diseases of the central nervous system (CNS) such as multiple sclerosis (MS). The emerging heterogeneity of pathology within MS lesions, and differential oligodendrocyte survival in particular, suggests that therapeutic strategies may need to be tailored to an individual patient's requirements. A number of therapeutic strategies have been proposed to enhance myelin repair in the CNS: cell transplantation, growth factor therapy, and antibody therapy, but each proposed therapy has different implications with respect to pathogenetic mechanisms of demyelination. Of these, antibody therapy is the most amenable to immediate application in patients-but a combination of therapeutic approaches may be required in practice.
Paz Soldan
M Mateo
MM
Program in Molecular Neuroscience, Mayo Medical and Graduate Schools, 200 First Street SW, Rochester, MN 55905, USA.
Rodriguez
Moses
M
D000818:Animals; D002493:Central Nervous System Diseases / Q000503:physiopathology / Q000628:therapy; D003711:Demyelinating Diseases / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D051379:Mice; D009103:Multiple Sclerosis / Q000503:physiopathology* / Q000628:therapy*; D009186:Myelin Sheath / Q000378:metabolism*